<DOC>
	<DOC>NCT00353964</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.</brief_summary>
	<brief_title>Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<criteria>be male or female who has undergone unilateral cataract extraction by phacoemulsification (PHACO) method with implantation of a posterior chamber intraocular lens have unstable glaucoma have an active bacterial and/or viral infection use any ocular or systemic antiinflammatory agents within 1 week prior to enrollment and for the duration of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>